- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00564148
Intravitreal Avastin in Proliferative Retinopathies (SITE-App)
Intravitreal Injections With Avastin in Proliferative Retinopathies Related to the Production of VEGF Having Different Causes
Study Overview
Detailed Description
Proliferative retinopathies due to different causes represent important causes for the visual acuity loss. Conventional treatments may sometimes improve the visual function, whereas other times, the visual acuity continue to decrease, in spite of all the medical, surgical or laser treatments.
Intravitreal injections with anti-VEGF agents (ex. Avastin for our trial) seem to be an important tool for certain difficult situations in which at the ocular fundus, out of different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new pathologic vessels appear, causing devastating changes in the posterior and anterior segment as well.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Iasi, Romania, 700377
- Ochiul Diabetic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- clinical diagnosis of a proliferative retinopathy (AGE RELATED MACULAR DEGENERATION,DIABETIC PROLIFERATIVE RETINOPATHY, etc)
- distance acuity < 0.5
- age > 20 years
Exclusion Criteria:
- noncooperative patients
- ocular infections / inflammations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: A,1, II
|
2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The following parameters will be assessed in order to evaluate the Avastin effect: visual acuity, lesions's area at the ocular fundus
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The intraocular pressure will be measured during the whole study in order to assess the possible side effects of Avastin injections
Time Frame: one year
|
one year
|
Collaborators and Investigators
Investigators
- Principal Investigator: NARCISA IANOPOL, researcher, Ophthalmological Association Edelweiss
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Retinal Diseases
- Metaplasia
- Neovascularization, Pathologic
- Retinal Neovascularization
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- AVAST-ro-1
- SITE-App
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Neovascularization
-
Instituto de Olhos de GoianiaUnknownChoroidal Retinal NeovascularizationBrazil
-
Notal Vision Inc.RecruitingRetinal NeovascularizationUnited States
-
Notal Vision Inc.CompletedRetinal NeovascularizationUnited States
-
Federico II UniversityCompleted
-
Fondation Ophtalmologique Adolphe de RothschildCompletedRetinal NeovascularizationFrance
-
University Hospital, GhentRecruitingMacular Edema | Retinal NeovascularizationBelgium
-
University of MelbourneCompletedChoroidal Neovascularization | Retinal Pigment Epithelial DetachmentAustralia
-
Tianjin Medical UniversityTerminatedThe Mechanism of Retinal Neovascularization of Diabetic | Retinopathy.China
-
Federico II UniversityRecruiting
-
Salutaris Medical Devices, Inc.Active, not recruitingMacular Degeneration, Choroidal NeovascularizationUnited States
Clinical Trials on Avastin
-
Shanghai Henlius BiotechCompletedHealthy Male SubjectsChina
-
Instituto Universitario de Oftalmobiología Aplicada...CompletedMacular Edema | Retinal Vein OcclusionSpain
-
Northwell HealthFeinstein Institute for Medical Research; Hofstra North ShoreSuspendedVestibular SchwannomaUnited States
-
Ronald HoffmanNational Cancer Institute (NCI); Myeloproliferative Disorders-Research ConsortiumTerminated
-
Children's Hospital Los AngelesTemporarily not availableRetinopathy of PrematurityUnited States
-
Instituto Universitario de Oftalmobiología Aplicada...CompletedChoroidal Subfoveal/Juxtafoveal Neovascularization in High MyopiaSpain
-
University of Southern CaliforniaCompletedDiabetic Retinopathy | Retinal DetachmentUnited States
-
Hoffmann-La RocheCompletedGlioblastoma MultiformeSwitzerland, France, United Kingdom, Denmark
-
Universidad Autonoma de San Luis PotosíUnknownRetinopathy of PrematurityMexico